

Zulresso Enrollment Form

Fax Referral To: 1-800-323-2445 Phone: 1-800-678-1831 Email Referral To: Customer.ServiceFax@CVSHealth.com

1 PATIENT INFORMATION (Com	plete or include demographic :	sheet)	
Patient Name:	· · · · · · · · · · · · · · · · · · ·	DOB:	Gender: 🗌 Male 🔲 Female
	City,		
Preferred Contact Methods: Phone (t	o primary # provided below) 🗌 Text	(to cell # provided be	low) 🔝 Email (to email provided
below) Note: Carrier charges may apply. By pro	viding the phone number(s) and amai	il addross abova you (are concenting to receive
automated calls, emails and/or text mes		-	-
data rates apply. Message frequency val			
phone.			-,
Primary Phone:			
Email:			
Parent/Caregiver/Legal Guardian Name	e (Last, First): Rel	ationship to patient: _	
2 PRESCRIBER INFORMATION			
_ Prescriber's Name:	Practice Na	ame:	
	City, State, ZIP:		
Group or Hospital:			
Phone: Fax			
-			
Primary Insurance Name:			
Pharmacy Plan Name:		Pharma	cy Plan Telephone:
Policy ID:	Group #:	RX BIN #:	RX PCN #:
DIAGNOSIS AND CLINICAL IN Needs by Date: Ship t			
Note: Zulresso is available only through a	a restricted distribution program calle	d the ZULRESSO REM	S because of the risk of serious
harm resulting from excessive sedatio	n and sudden loss of consciousness	during the Zulresso	infusion. Zulresso is intended fo
infusion only in a certified Health Care	Setting.		
Will REMS certified health care facility di	lute and prepare product for infusion	administration.	☐ Yes ☐ No
If 'No,' does REMS certified health care fa			
	active require specially pharmacy to t	anato ana propuro zai	
Diagnosis (ICD-10):			
F53.0 Postpartum Depression	Other Code: Description	on:	-
Patient Clinical Information:			
Allergies:	Height: in/cm	Weight:lb/kg	
5 TREATMENT INFORMATION F	FOR PRESCRIBERS		
Before submitting this form, please en	sure:		
 Provider identifies whether or not spec 		and prepared Zulresso	o for infusion administration
(check 1 box)			
	ense diluted and prepared Zulresso f	or infusion administrat	tion.
	paration of Zulresso is required, please		
CMS ambulatory infusion			

Specialty Pharmacy to dispense Zulresso vials only.

• Copies of the health insurance and prescription drug coverage cards are provided.

	Please Complete Patient and P	rescriber Information	
Patient Name:	Patient DOB:	Patient Phone:	
Prescriber Name	Prescriber Phone		

TREATMENT INFORMATION FOR PRESCRIBERS continued

Zulresso prescribing highlights

- Zulresso is administered as a continuous IV infusion over 60 hours as follows:
 - 0 to 4 hours: Initiate with a dosage of 30 mcg/kg/hour
 - 4 to 24 hours: Increase dosage to 60 mcg/kg/hour
 - 24 to 52 hours: Increase dosage to 90 mcg/kg/hour (alternatively consider a dosage of 60 mcg/kg/hour for those who do not tolerate 90 mcg/kg/hour)
 - o 52 to 56 hours: Decrease dosage to 60 mcg/kg/hour
 - 56 to 60 hours: Decrease dosage to 30 mcg/kg/hour
- Prior to infusion, each vial of Zulresso must be diluted with 40ml Sterile Water for Injection and 40ml of 0.9 % Sodium Chloride Injection for a total volume of 100ml to achieve a concentration of 1mg/ml.
- After dilution, the product can be stored in infusion bags under refrigerated conditions for up to 96 hours. However, given that the diluted product can be used for only 12 hours at room temperature, each 60-hour infusion will require the preparation of at least 5 infusion bags.

For additional information, please refer to full prescribing information: Zulresso Prescribing Information

6 PRESCRIPTION INFORMATION

NOTE: The prescription form below should only be used if permitted by the applicable law in your state and if you are not required by law to use an official/tamper-evident prescription form. The prescriber should include all required elements of a controlled substance prescription.

Patient Name (First and Last):		Patient Date of Birth:
Patient Address:		
Drug Name, strength, and dosage form:		
Directions/Sig:		
Quantity Authorized (Numeric) ((Written)	
Physician Name:	Phys	sician DEA #:
Physician Address:		

7 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED) Please note regulations around

transmission of prescriptions for controlled substances vary state by state.

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution /	May Substitute / Product Selection Permitted /
DAW / May Not Substitute	Substitution Permissible
Prescriber's Signature:Date:	Prescriber's Signature:Date:
CA MA NC & DB: Interchange is mandated unless Prescriber writes the words "No Substitution"	ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby CVS Specialty[®] and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

patient privacy is important to us. Our employees are trained regarding the appropriate way to handle patients' private health information. This document contains references to brandname prescription drugs that are trademarked, or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.